Use of aminocaproic acid (ACA) in extra-amniotic MTP in patients on anti-coagulant therapy.
A case of rheumatic heart disease (RHD) with prosthetic mitral valve endocarditis receiving anticoagulation with heparin, underwent medical termination of pregnancy in a second trimester. The following report entails the use of aminocaproic acid (ACA) in preventing excessive bleeding during and after the procedure, while the patient continued to receive anticoagulant therapy.
Kale
P P
PP
Dr JC Patel Haematology Department, Seth G S Medical College, Parel, Bombay, Maharashtra.
Shah
M A
MA
Pathare
A V
AV
D000032:Abortion, Therapeutic / Q000379:methods*; D000328:Adult; D000614:Aminocaproates / Q000008:administration & dosage / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology; D004696:Endocarditis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008944:Mitral Valve Insufficiency / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D012214:Rheumatic Heart Disease / Q000150:complications* / Q000188:drug therapy / Q000601:surgery
D000614:Aminocaproates; D006493:Heparin